Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007004869) TREATMENT OF TUMORS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/004869 International Application No.: PCT/NL2006/000329
Publication Date: 11.01.2007 International Filing Date: 03.07.2006
IPC:
A61K 38/06 (2006.01) ,A61K 38/07 (2006.01) ,A61K 38/08 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
06
Tripeptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
07
Tetrapeptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08
Peptides having 5 to 11 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
BIOTEMPT B.V. [NL/NL]; Hoge Linthorst 1 NL-7958 NZ Koekange, NL (AllExceptUS)
KHAN, Nisar Ahmed [NL/NL]; NL (UsOnly)
BENNER, Robbert [NL/NL]; NL (UsOnly)
WENSVOORT, Gert [NL/NL]; NL (UsOnly)
Inventors:
KHAN, Nisar Ahmed; NL
BENNER, Robbert; NL
WENSVOORT, Gert; NL
Agent:
VAN LOON, C.J.J.; C/o Vereenigde Johan De Wittlaan 7 NL-2517 JR The Hague, NL
Priority Data:
60/696,65705.07.2005US
Title (EN) TREATMENT OF TUMORS
(FR) TRAITEMENT DE TUMEURS
Abstract:
(EN) Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory or anti-tumor compounds. Such anti-tumor compounds are useful for the treatment or prevention of tumors and can be used as part of a pharmaceutical composition. The invention provides a pharmaceutical composition for the treatment of a subject suffering from or belived to be suffering from a tumor, said pharmaceutical composition comprising: a therapeutically effective amount of anti-tumor peptide or a functional analogue or derivative thereof together with a pharmaceutically acceptable diluent, wherein the peptide is preferably selected from the group VVC, LAG, AQG, LQGV, QVVC, MTRV, AQGV, LAGV, LQAV, PGCP, VGQL, RVLQ, EMFQ, AVAL, FVLS, NMWD, LCFL, FSYA, FWVD, AFTV, LGTL, QLLG, YAIT, APSL, ITTL, QALG, GVLC, NLIN, SPIE, LNTI, LHNL, CPVQ, EVVR, MTEV, EALE, TLAVE, VEGNL, LNEAL, VLPALP, MGGTWA, LTCDDP, VLPALPQ, VCNYRDV, CPRGVNP, QPLAPLVG or DINGFLPAL.
(FR) Alors que l'on pensait précédemment que les plus petits produits de dégradation des protéines n'avaient pas de fonction biologique spécifique propre, il s'avère que le corps peut utiliser le processus normal de dégradation protéolytique pour générer d'importants composés tels que des composés de régulation génique ou antitumoraux. De tels composés antitumoraux sont utilisés dans le traitement ou la prévention de tumeurs et peuvent être incorporés dans une composition pharmaceutique. Cette invention concerne une composition pharmaceutique servant au traitement d'un sujet souffrant ou supposé souffrir d'une tumeur, laquelle composition pharmaceutique renferme: une quantité thérapeutiquement efficace d'un peptide antitumoral ou d'un analogue ou dérivé fonctionnel de celui-ci, ainsi qu'un diluant pharmaceutiquement acceptable, lequel peptide est de préférence sélectionné dans le groupe VVC, LAG, AQG, LQGV, QVVC, MTRV, AQGV, LAGV, LQAV, PGCP, VGQL, RVLQ, EMFQ, AVAL, FVLS, NMWD, LCFL, FSYA, FWVD, AFTV, LGTL, QLLG, YAIT, APSL, ITTL, QALG, GVLC, NLIN, SPIE, LNTI, LHNL, CPVQ, EVVR, MTEV, EALE, TLAVE, VEGNL, LNEAL, VLPALP, MGGTWA, LTCDDP, VLPALPQ, VCNYRDV, CPRGVNP, QPLAPLVG ou DINGFLPAL.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
NZ564837KR1020080033331IL188430SG163567EP1904086JP2009500320
CN101217971CA2614084AU2006266609IN599/CHENP/2008